Format

Send to

Choose Destination
See comment in PubMed Commons below
Biomark Insights. 2007 Oct 3;2:347-60.

Proteomics and mass spectrometry for cancer biomarker discovery.

Author information

1
Gonda/UCLA Breast Cancer Research Laboratory.

Abstract

Proteomics is a rapidly advancing field not only in the field of biology but also in translational cancer research. In recent years, mass spectrometry and associated technologies have been explored to identify proteins or a set of proteins specific to a given disease, for the purpose of disease detection and diagnosis. Such biomarkers are being investigated in samples including cells, tissues, serum/plasma, and other types of body fluids. When sufficiently refined, proteomic technologies may pave the way for early detection of cancer or individualized therapy for cancer. Mass spectrometry approaches coupled with bioinformatic tools are being developed for biomarker discovery and validation. Understanding basic concepts and application of such technology by investigators in the field may accelerate the clinical application of protein biomarkers in disease management.

KEYWORDS:

Biomarkers; Cancer; Mass spectrometry; Proteomics

PMID:
19662217
PMCID:
PMC2717808
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Libertas Academica Icon for PubMed Central
    Loading ...
    Support Center